QIMR Berghofer Medical Research Institute Selects JPT’s GxP PepMix™ Peptide Pool Technology to Support its Phase I/II Clinical Trials of Adoptive Immunotherapy for Human Cytomegalovirus-associated Diseases

NEWS RELEASE MAY 13, 2014    
JPT Peptide Technologies GmbH (JPT), a wholly-owned subsidiary of BioNTech AG (Mainz, Germany), and Prof. Khanna of the QIMR Centre for  Immunotherapy and Vaccine Development (Brisbane, Australia) have agreed on the use of JPT’s GxP PepMix™ Peptide Pool Platform to support their clinical adoptive immunotherapy trial of HCMV specific T cells to treat glioblastoma and transplant patients with HCMV-associated complications.
Within the collaboration JPT will assemble and provide HCMV peptide pools using its proprietary GxP PepMix™ Technology for antigen specific stimulation of T-cell responses.
Holger Wenschuh, CEO at JPT comments, "The collaboration with QIMR Berghofer represents the latest successful milestone in our efforts to establish our unique GxP PepMix™ Technology as the gold standard for manufacturing clinical grade peptide pools for T-cell therapies".    

About JPT Peptide Technologies GmbH

JPT Peptide Technologies GmbH is an DIN ISO 9001:2008 certified research and development partner and innovative service provider for peptide related projects.  JPT’s key technologies SPOT™ – for ultra-high-throughput peptide synthesis and screening, PepStar™ – for high-content peptide microarrays, PepTrack™  - for flexible peptide library assembly, PepMix™ – for antigen specific T-cell stimulation using peptide pools, and SpikeTides™ – for protein biomarker quantification accelerate research and development in areas such as immune monitoring, vaccine development, peptide biomarker discovery, peptide lead identification and optimization, enzyme profiling and proteomics.

Stay in touch and be the first to receive the latest news!